Telerobotic surgery is transitioning from experimental demonstrations to broader clinical and regulatory development, and SS Innovations International (NASDAQ: SSII) is emerging as a key player in this evolving field. A recent MedTech Dive article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s progress and the challenges of remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers. The report underscores the growing relevance of remote surgical capabilities, which could reshape access to specialized care globally.
Dr. Sudhir Srivastava, founder and CEO of SS Innovations and a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation, and the central technical question is how much distance can be introduced without compromising responsiveness. That question is becoming increasingly practical as the company’s SSi Mantra system accumulates real-world experience. As of September 28, 2026, SS Innovations reported 195 robotic telesurgeries using the SSi Mantra, including cardiac procedures and long-distance operations. The company’s installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503.
The SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. These developments signal that telerobotic surgery is gaining traction in diverse healthcare settings, potentially addressing surgeon shortages and enabling remote expertise to reach underserved regions. For SS Innovations, the growing clinical footprint provides valuable data and experience as it pursues U.S. FDA clearance and European Union CE marking to expand into additional international markets.
The regulatory pathway is critical. U.S. and European approvals would open access to some of the world’s largest healthcare markets, where demand for minimally invasive and remote surgical options is rising. However, questions remain about infrastructure, liability, and standards for remote procedures. The MedTech Dive article noted that while telerobotic surgery is advancing globally, U.S. adoption will depend on addressing these regulatory and logistical hurdles. SS Innovations’ progress in telesurgery, including cardiac cases, could inform those discussions.
For investors and industry observers, the company’s metrics offer a window into its commercial momentum. The 45% increase in installed systems and the accumulation of over 14,500 procedures suggest growing adoption. The company’s focus on telesurgery differentiates it in a competitive robotics market. More details on the MedTech Dive report and SS Innovations’ position are available through the company’s newsroom at https://ibn.fm/SSII, and the full article can be accessed at Read More. Additional context is available via https://ibn.fm/4ZLvL, and the original release was distributed by NEWMEDIAWIRE. As telerobotic surgery gains ground, SS Innovations’ ability to navigate regulatory and technical challenges will determine whether it can translate early experience into widespread clinical adoption.
